Director/PDMR Shareholding
London, 21 August 2020
NOTIFICATION OF TRANSACTIONS OF DIRECTORS/PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||||||||
a) | Name | Giorgi Pailodze | ||||||||||||||||||
2. | Reason for the notification | |||||||||||||||||||
a) | Position / status | PDMR, Deputy CEO | ||||||||||||||||||
b) | Initial notification / amendment | Initial notification | ||||||||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||
a) | Name | Bank of Georgia Group PLC | ||||||||||||||||||
b) | LEI: | 213800XKDG12NQG8VC53 | ||||||||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||||||
a) | Description of the financial instrument, type of instrument
Identification Code
| ordinary shares of £0.01 each in Bank of Georgia Group PLC
GB00BF4HYT85 | ||||||||||||||||||
b) | Nature of the transaction | Acquisition | ||||||||||||||||||
c) | Price(s) and volume(s) |
| ||||||||||||||||||
d) | Aggregated information | In total, 4,158 ordinary shares were bought at an average price per ordinary share of £7.89 resulting in an aggregate volume price of £32,813. | ||||||||||||||||||
e) | Dates of the transaction | 20 August 2020 | ||||||||||||||||||
f)
| Place of the transaction | London Stock Exchange (XLON) | ||||||||||||||||||
Name of authorised official of issuer responsible for making notification:
Link Company Matters Limited, Company Secretary
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.